Sign In
Upcoming Event
Free Newsletter
Precision Medicine Group acquires Project Farma, adds to cell and gene therapy expertise
Precision Medicine Group acquires Project Farma, adds to cell and gene therapy expertise
Listen to this articleBethesda-based Precision Medicine Group Thursday acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies.
Project Farma will be part of Precision for Medicine, PMG’s research and development services arm.
Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma’s unique expertise to Precision’s suite of end-to-end cell and gene therapy capabilities to support development and commercialization.
Led by executive leaders Anshul Mangal, John Khoury, and Tony Khoury, Project Farma has distinguished itself as a global leader in planning and implementing complex biomanufacturing strategies and facilities for clients that range from start-up biotechnology companies to global biopharmaceutical companies and academic medical centers.
Project Farma has led more than a dozen manufacturing facility builds with capital investments greater than $1 billion, including some of the leading FDA-approved cell and gene therapy medicines.
